Latest Cytori Therapeutics Inc (CYTX) Headlines
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Cytori Reports Fourth Quarter and Full Year 2013 Business and Financial Results
Business Wire - Tue Mar 11, 3:05PM CDT
Cytori Therapeutics (NASDAQ: CYTX) reports its fourth quarter and year end 2013 business and financial results and provides an outlook for 2014.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Cytori Therapeutics to Present at the 26th Annual Roth Conference on March 12
Business Wire - Thu Mar 06, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present and provide a corporate update from the 26th Annual Roth Conference on Wednesday, March 12, at 10:30 AM PT.
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 11
Business Wire - Tue Mar 04, 11:53AM CST
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Tuesday, March 11, 2014 at 5:00 PM Eastern Time.
Okyanos Heart Institute Inks Deal with Cytori Therapeutics For Long-Term Supply Agreement
PRWeb - Fri Feb 21, 11:08AM CST
Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease using adult stem cell therapy, and Cytori Therapeutics have announced that they have established a ten year supply agreement for the Celution™ System family of products to be utilized by the Okyanos Heart Institute.
Hot Stock: Cytori Therapeutics, Shares Gain 8.5% (CYTX)
Comtex SmarTrend(R) - Fri Feb 21, 10:11AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 8.5% to $3.35 on 2.5x average daily volume. Thus far today, Cytori Therapeutics has traded 1.3 million shares, vs. average volume of 510,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's 0.2%) and outperformed the S&P 500 (8.5% to the S&P's 0.3%) during today's trading.
5 Stocks Under $10 Ready to Explode
at The Street - Thu Feb 20, 12:34PM CST
Trading stocks under $10 can really pay off -- if you know what you're doing.
Commit To Buy Cytori Therapeutics At $2.50, Earn 17.8% Annualized Using Options
StockOptionsChannel.com - Tue Feb 18, 10:31AM CST
Investors considering a purchase of Cytori Therapeutics Inc shares, but tentative about paying the going market price of $3.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Feb 14, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
Cytori Therapeutics Down 8.4%, Shares Slide into the Red (CYTX)
Comtex SmarTrend(R) - Mon Jan 27, 11:44AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's worst performing low-priced stocks, down 8.4% to $2.63 on 1.1x average daily volume. Thus far today, Cytori Therapeutics has traded 636,000 shares, vs. average volume of 593,000 shares per day. The stock has underperformed the Dow (-8.4% to the Dow's -0.4%) and underperformed the S&P 500 (-8.4% to the S&P's -0.8%) during today's trading.
Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 6:25AM CST
Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue?
Stock to Watch: Cytori Therapeutics Up 5.4% (CYTX)
Comtex SmarTrend(R) - Mon Jan 13, 12:47PM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 5.4% to $3.10 on 1.1x average daily volume. Thus far today, Cytori Therapeutics has traded 582,000 shares, vs. average volume of 552,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.6%) and outperformed the S&P 500 (5.4% to the S&P's -0.7%) during today's trading.
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives
ACCESSWIRE - Mon Jan 13, 9:09AM CST
Thanks to new legislation being approved by the Upper House of Japan's Parliament in November, Japan's so-called "drug lag," specifically with respect to regenerative medicine, will likely become a thing of the past. By retooling the framework of the regulatory process for regenerative medicine products, the nation has shifted from a global drug development laggard to one of the most proactive countries on the planet aiming to safely expedite growth in the burgeoning, yet volatile, stem cell industry to meet the needs of a rapidly expanding aging population. The new laws are designed to promote innovation and could provide a clear channel to rapid commercialization that will benefit industry-leading companies like Cellular Dynamics International, Inc. (NASDAQ: ICEL), Athersys, Inc. (NASDAQ: ATHX) and Cytori Therapeutics, Inc. (NASDAQ: CYTX).
Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:39AM CST
Vical Incorporated was a big mover last session, as its shares rose almost 15% on the day.
Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:57AM CST
Incyte Corp. (INCY) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Cytori to Initiate U.S. Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries
Business Wire - Mon Jan 13, 7:00AM CST
Cytori Therapeutics (NASDAQ:CYTX) has received Investigational Device Exemption (IDE) approval from the FDA to begin a prospective clinical trial to evaluate the safety and feasibility of Cytori Cell Therapy as a potential treatment for hamstring injuries. The trial, referred to as RECOVER, will begin as a ten-patient, open label study in 2014. Following a 90-day assessment of the first ten patients, Cytori is approved by the FDA to expand RECOVER to a multi-dose, multi-center, double-blind, placebo-controlled trial. Cytori Cell Therapy is derived from the Company's Celution(R) System, which enables access to a patient's own adipose-derived regenerative cells (ADRCs) at the point-of-care.
Cytori Therapeutics (CYTX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 8:21AM CST
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Stock to Watch: Cytori Therapeutics Up 11.0% (CYTX)
Comtex SmarTrend(R) - Wed Jan 08, 10:13AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 11.0% to $2.92 on 1.7x average daily volume. Cytori Therapeutics has traded 883,000 shares thus far today, vs. average volume of 517,000 shares per day. The stock has outperformed the Dow (11.0% to the Dow's -0.4%) and outperformed the S&P 500 (11.0% to the S&P's 0.0%) during today's trading.
Cytori Announces Presentation at Biotech Showcase(TM) on January 13
Business Wire - Tue Jan 07, 7:00AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will webcast their corporate presentation at the Biotech Showcase(TM) at 11:00 AM PT (2:00 PM ET) on Monday, January 13. The presentation will be held in the Mission II room of the Parc 55 Wyndham Hotel in San Francisco.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Cytori Reports Fourth Quarter and Full Year 2013 Business and Financial Results
Business Wire - Tue Mar 11, 3:05PM CDT
Cytori Therapeutics (NASDAQ: CYTX) reports its fourth quarter and year end 2013 business and financial results and provides an outlook for 2014.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Cytori Therapeutics to Present at the 26th Annual Roth Conference on March 12
Business Wire - Thu Mar 06, 7:01AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present and provide a corporate update from the 26th Annual Roth Conference on Wednesday, March 12, at 10:30 AM PT.
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 11
Business Wire - Tue Mar 04, 11:53AM CST
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Tuesday, March 11, 2014 at 5:00 PM Eastern Time.
Okyanos Heart Institute Inks Deal with Cytori Therapeutics For Long-Term Supply Agreement
PRWeb - Fri Feb 21, 11:08AM CST
Okyanos Heart Institute, whose mission it is to bring a new standard of care and a better quality of life to patients with coronary artery disease using adult stem cell therapy, and Cytori Therapeutics have announced that they have established a ten year supply agreement for the Celution™ System family of products to be utilized by the Okyanos Heart Institute.
Hot Stock: Cytori Therapeutics, Shares Gain 8.5% (CYTX)
Comtex SmarTrend(R) - Fri Feb 21, 10:11AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 8.5% to $3.35 on 2.5x average daily volume. Thus far today, Cytori Therapeutics has traded 1.3 million shares, vs. average volume of 510,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's 0.2%) and outperformed the S&P 500 (8.5% to the S&P's 0.3%) during today's trading.
5 Stocks Under $10 Ready to Explode
at The Street - Thu Feb 20, 12:34PM CST
Trading stocks under $10 can really pay off -- if you know what you're doing.
Commit To Buy Cytori Therapeutics At $2.50, Earn 17.8% Annualized Using Options
StockOptionsChannel.com - Tue Feb 18, 10:31AM CST
Investors considering a purchase of Cytori Therapeutics Inc shares, but tentative about paying the going market price of $3.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Feb 14, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
Cytori Therapeutics Down 8.4%, Shares Slide into the Red (CYTX)
Comtex SmarTrend(R) - Mon Jan 27, 11:44AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's worst performing low-priced stocks, down 8.4% to $2.63 on 1.1x average daily volume. Thus far today, Cytori Therapeutics has traded 636,000 shares, vs. average volume of 593,000 shares per day. The stock has underperformed the Dow (-8.4% to the Dow's -0.4%) and underperformed the S&P 500 (-8.4% to the S&P's -0.8%) during today's trading.
Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 6:25AM CST
Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue?
Stock to Watch: Cytori Therapeutics Up 5.4% (CYTX)
Comtex SmarTrend(R) - Mon Jan 13, 12:47PM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 5.4% to $3.10 on 1.1x average daily volume. Thus far today, Cytori Therapeutics has traded 582,000 shares, vs. average volume of 552,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.6%) and outperformed the S&P 500 (5.4% to the S&P's -0.7%) during today's trading.
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives
ACCESSWIRE - Mon Jan 13, 9:09AM CST
Thanks to new legislation being approved by the Upper House of Japan's Parliament in November, Japan's so-called "drug lag," specifically with respect to regenerative medicine, will likely become a thing of the past. By retooling the framework of the regulatory process for regenerative medicine products, the nation has shifted from a global drug development laggard to one of the most proactive countries on the planet aiming to safely expedite growth in the burgeoning, yet volatile, stem cell industry to meet the needs of a rapidly expanding aging population. The new laws are designed to promote innovation and could provide a clear channel to rapid commercialization that will benefit industry-leading companies like Cellular Dynamics International, Inc. (NASDAQ: ICEL), Athersys, Inc. (NASDAQ: ATHX) and Cytori Therapeutics, Inc. (NASDAQ: CYTX).
Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:39AM CST
Vical Incorporated was a big mover last session, as its shares rose almost 15% on the day.
Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:57AM CST
Incyte Corp. (INCY) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Cytori to Initiate U.S. Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries
Business Wire - Mon Jan 13, 7:00AM CST
Cytori Therapeutics (NASDAQ:CYTX) has received Investigational Device Exemption (IDE) approval from the FDA to begin a prospective clinical trial to evaluate the safety and feasibility of Cytori Cell Therapy as a potential treatment for hamstring injuries. The trial, referred to as RECOVER, will begin as a ten-patient, open label study in 2014. Following a 90-day assessment of the first ten patients, Cytori is approved by the FDA to expand RECOVER to a multi-dose, multi-center, double-blind, placebo-controlled trial. Cytori Cell Therapy is derived from the Company's Celution(R) System, which enables access to a patient's own adipose-derived regenerative cells (ADRCs) at the point-of-care.
Cytori Therapeutics (CYTX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 8:21AM CST
Cytori Therapeutics, Inc. (CYTX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Stock to Watch: Cytori Therapeutics Up 11.0% (CYTX)
Comtex SmarTrend(R) - Wed Jan 08, 10:13AM CST
Cytori Therapeutics (NASDAQ:CYTX) is one of today's best performing low-priced stocks, up 11.0% to $2.92 on 1.7x average daily volume. Cytori Therapeutics has traded 883,000 shares thus far today, vs. average volume of 517,000 shares per day. The stock has outperformed the Dow (11.0% to the Dow's -0.4%) and outperformed the S&P 500 (11.0% to the S&P's 0.0%) during today's trading.
Cytori Announces Presentation at Biotech Showcase(TM) on January 13
Business Wire - Tue Jan 07, 7:00AM CST
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will webcast their corporate presentation at the Biotech Showcase(TM) at 11:00 AM PT (2:00 PM ET) on Monday, January 13. The presentation will be held in the Mission II room of the Parc 55 Wyndham Hotel in San Francisco.
